News » LEGAL/JUDGEMENTS News » Back To Story Page Send To Printer
Noven Files Patent Infringement Lawsuit against Watson Pharmaceuticals

MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of New Jersey against Watson Pharmaceuticals ("Watson") for infringement of certain Noven patents (the "Patents") by Watson.

The lawsuit was filed as a result of an Abbreviated New Drug Application (ANDA) submission by Watson seeking FDA approval to market and sell a generic version of Daytranaģ (methylphenidate transdermal system) prior to the scheduled expiration of the Patents in 2018. The lawsuit reflects Novenís commitment to vigorously defending its intellectual property rights against infringement.

Under the Hatch-Waxman Act, because Noven filed this patent infringement lawsuit within 45 days of receiving a Paragraph IV notification letter from Watson, the FDA cannot approve Watsonís ANDA for 30 months (until March 2014), unless the district court finds the Patents invalid or not infringed before the 30 months pass.

About Noven

Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Novenís business and operations are focused in three principal areas Ė transdermal drug delivery and related manufacturing, the Novogyne joint venture, and Noven Therapeutics, Novenís specialty pharmaceutical unit. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers and its industry partners. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., and serves as Hisamitsuís U.S. growth platform in prescription pharmaceuticals. For more information about Noven, visit For information about Hisamitsu, visit

© 1998-2015, LLC
Send To Printer  |  Back To Story Page